Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine ...

Factoring out nucleotide-level mutation biases from antibody language models dramatically improves prediction of functional mutation effects while reducing computational cost by orders of magnitude.

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...

Genetic mutations are the primary cause of most rare diseases. Although each condition affects a small fraction of the population, the global impact is significant, with an estimated 300 million ...

MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 ...